SCHEMBL29927520

SCHEMBL29927520

C[C@H]1CN(C(=O)OCc2ccccc2)CCN1C[C@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.51
PDK2 Q15119 1/20 0.51
PDK3 Q15120 1/20 0.51
PDK4 Q16654 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 1/20 0.47
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
CYP2C19 P33261 1/20 0.46
PARP1 P09874 1/20 0.46
YAP1 P46937 2/20 0.45
GRIN2B Q13224 4/20 0.45
GPR119 Q8TDV5 2/20 0.44
STS P08842 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26927558 0.96 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30731906 0.96 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30706191 0.96 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30706025 0.96 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL29927532 0.94 PDK1 (0.52) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30731942 0.89 PDK1 (0.45) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL29927363 0.89 PDK1 (0.50) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30602886 0.87 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTJAK2
SCHEMBL30179036 0.87 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTJAK2
SCHEMBL26705305 0.87 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559506-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 US disclosed
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-10-31 US disclosed
US-11981683-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-14 US disclosed
EP-4308557-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-01-24 EP disclosed
CN-117321046-A Indazole-based compounds and related methods of use 阿维纳斯企业公司 2023-12-29 CN disclosed
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 US disclosed
WO-2022198112-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-12559506-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, CLK2 PDK1 2125/4885PDK2 1878/4885PDK3 1663/4885
US-11981683-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.